- Home
- MAGH vs CGTX Comparison
MAGH vs CGTX Comparison
Compare MAGH & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MAGH
- CGTX
- Stock Information
- Founded
- MAGH 2012
- CGTX 2007
- Country
- MAGH Singapore
- CGTX United States
- Employees
- MAGH N/A
- CGTX N/A
- Industry
- MAGH Engineering & Construction
- CGTX Biotechnology: Pharmaceutical Preparations
- Sector
- MAGH Industrials
- CGTX Health Care
- Exchange
- MAGH Nasdaq
- CGTX Nasdaq
- Market Cap
- MAGH 51.8M
- CGTX 53.4M
- IPO Year
- MAGH 2025
- CGTX 2021
- Fundamental
- Price
- MAGH N/A
- CGTX $1.54
- Analyst Decision
- MAGH
- CGTX Strong Buy
- Analyst Count
- MAGH 0
- CGTX 3
- Target Price
- MAGH N/A
- CGTX $2.83
- AVG Volume (30 Days)
- MAGH 1.5M
- CGTX 8.5M
- Earning Date
- MAGH 01-01-0001
- CGTX 08-07-2025
- Dividend Yield
- MAGH N/A
- CGTX N/A
- EPS Growth
- MAGH N/A
- CGTX N/A
- EPS
- MAGH 0.03
- CGTX N/A
- Revenue
- MAGH $13,529,576.00
- CGTX N/A
- Revenue This Year
- MAGH N/A
- CGTX N/A
- Revenue Next Year
- MAGH N/A
- CGTX N/A
- P/E Ratio
- MAGH $50.79
- CGTX N/A
- Revenue Growth
- MAGH 10.71
- CGTX N/A
- 52 Week Low
- MAGH $1.45
- CGTX $0.22
- 52 Week High
- MAGH $5.15
- CGTX $1.97
- Technical
- Relative Strength Index (RSI)
- MAGH N/A
- CGTX 77.80
- Support Level
- MAGH N/A
- CGTX $1.15
- Resistance Level
- MAGH N/A
- CGTX $0.74
- Average True Range (ATR)
- MAGH 0.00
- CGTX 0.19
- MACD
- MAGH 0.00
- CGTX 0.09
- Stochastic Oscillator
- MAGH 0.00
- CGTX 69.59
About MAGH Magnitude International Ltd Ordinary Shares
Magnitude International Ltd is providing electrical installation services to customers in both the private and public sectors in Singapore. It includes the planning, design, material selection, installation, testing, commissioning and certification of the electrical equipment/systems to be installed. The Group's revenue is derived from Singapore.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.